Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells

Clinical Cancer Research

Volumn 15, Issue 12, 2009, Pages 4077-4084

  Miyachi, Mitsuru ^a   Kakazu, Naoki ^b   Yagyu, Shigeki ^a   Katsumi, Yoshiki ^a   Tsubai Shimizu, Satoko ^a   Kikuchi, Ken ^a   Tsuchiya, Kunihiko ^a   Iehara, Tomoko ^a   Hosoi, Hajime ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DACTINOMYCIN; NUTLIN 3; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CULTURE MEDIUM; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DACTINOMYCIN; DRUG SYNERGISM; HUMANS; IMIDAZOLES; MUTATION, MISSENSE; NEOPLASMS, MUSCLE TISSUE; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; RHABDOMYOSARCOMA; TUMOR SUPPRESSOR PROTEIN P53; VINCRISTINE;

EID: 67449164584     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2955     Document Type: Article

References (33)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331 (Pubitemid 27131374)
2. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991;253:49-53. (Pubitemid 21917115)
3. Hollstein M, Shomer B, Greenblatt M, et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996;24:141-146 (Pubitemid 26085752)
4. Taylor AC, Shu L, Danks MK, et al. p53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol 2000;35:96-103.
5. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-27 (Pubitemid 28037193)
6. Momand J, Jung D, Wilczynski S, et al. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-3459 (Pubitemid 28347214)
7. Oliner JD, Kinzler KW, Meltzer PS, et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-83
8. Wang H, Nan L, Yu D, et al. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res 2001;7:3613-3624 (Pubitemid 33070002)
9. Zhang Z, Li M, Wang H, et al. Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A 2003;100:11636-11641 (Pubitemid 37205988)
10. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-848
11. Maerken TV, Speleman F, Vermeulen J, et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 2006;66:9646-9655 (Pubitemid 44623664)
12. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006;444:61-66 (Pubitemid 44684754)
13. Gu L, Zhu N, Findley HW, et al. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 2008;22:730-739 (Pubitemid 351552622)
14. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005;106:3150-3159 (Pubitemid 41565913)
15. Coll-Mulet L, Iglesias-Serret D, Santidrián AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006;107:4109-4114 (Pubitemid 43726820)
16. Hayashi Y, Sugimoto T, Horii Y, et al. Characterization of an embryonal rhabdomyosarcoma cell line showing amplification and over-expression of the N-myc oncogene. Int J Cancer 1990;45:705-711 (Pubitemid 20146133)
17. Kubo K, Naoe T, Utsumi KR, et al. Cytogenetic and cellular characteristics of a human embryonal rhabdomyosarcoma cell line, RMS-YM. Br J Cancer 1991;63:879-884
18. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DD C(T)) method. Methods 2001;25:402-408 (Pubitemid 34164012)
19. Kikuchi K, Tsuchiya K, Otabe O, et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun 2008;365:568-574 (Pubitemid 350181685)
20. Tsuchiya K, Hosoi H, Misawa-Furihata A, et al. Insulin-like growth factor-I has different effects on myogenin induction and cell cycle progression in human alveolar and embryonal rhabdomyosarcoma cells. Int J Oncol 2007;31:41-47
21. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
22. Kan CE, Patton JT, Stark GR, Jackson MW. p53-mediated growth suppression in response to nutlin-3 in cyclin D1transformed cells occurs independently of p21. Cancer Res 2007;67:9862-9868 (Pubitemid 47621234)
23. Ayan I, Dogan Ö, Kebudi R, et al. Immunohistochemical detection of p53 protein in rhabdomyosarcoma: association with clinicopathological features and outcome. J Pediatr Hematol Oncol 1997;19:48-53. (Pubitemid 27124058)
24. Boman F, Brel D, Antunes L, et al. Gene alterations and apoptosis in rhabdomyosarcoma. Pediatr Pathol Lab Med 1997;17:233-247 (Pubitemid 127774917)
25. Leuschner I, Langhans I, Schmitz R, et al. p53 and mdm-2 expression in rhabdomyosarcoma of childhood and adolescence: clinicopathologic study by the Kiel Pediatric Tumor Registry and the German Cooperative Soft Tissue Sarcoma Study. Pediatr Dev Pathol 2003;6:128-136 (Pubitemid 36433498)
26. Kojima K, Konopleva M, McQueen T, et al. Mdm2 inhibitor nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006;108:993-1000. (Pubitemid 44154636)
27. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 2006;103:1888-1893 (Pubitemid 43228788)
28. Barbieri E, Mehta P, Chen Z, et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther 2006;5:2358-2365 (Pubitemid 44530473)
29. Drakos E, Thomaides A, Medeiros LJ, et al. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res 2007;13:3380-3387 (Pubitemid 46944926)
30. Janz1 M, Stühmer T, Vassilev LT, et al. Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells. Leukemia 2007;21:772-779
31. Stühmer T, Chatterjee M, Hildebrandt M, et al. Non-genotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005;106:3609-3617 (Pubitemid 41609200)
32. Carvajal D, Tovar C, Yang H, et al. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 2005;65:1918-1924 (Pubitemid 40478621)
33. Efeyan A, Ortega-Molina A, Velasco-Miguel S, et al. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res 2007;67:7350-7357 (Pubitemid 47206565)